Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 1.97
- Piotroski Score 2.00
- Grade Equal-Weight
- Symbol (VACC)
- Company Vaccitech plc
- Price $5.00
- Changes Percentage (11.36%)
- Change $0.51
- Day Low $4.39
- Day High $5.09
- Year High $5.10
Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/12/2023
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.45
- Trailing P/E Ratio -3.448275862069
- Forward P/E Ratio -3.448275862069
- P/E Growth -3.448275862069
- Net Income $5.34 M
Income Statement
Quarterly
Annual
Latest News of VACC
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Merck & Co., Inc. (MRK) Projects 21% Upside with $140 Price Target as Keytruda and New Vaccines Drive Growth
The article discusses Merck & Co., Inc. in the context of the best healthcare stocks favored by hedge funds. It highlights the growth potential of the healthcare sector amid economic challenges and pr...
By Yahoo! Finance | 19 hours ago -
US farmers call for vaccine option to fight bird flu as wildfowl migration begins
U.S. farmers urge the Biden administration to allow vaccinations for poultry and cows to combat bird flu outbreaks that have devastated flocks. Vaccinations could protect livestock and prevent further...
By Yahoo! Finance | 3 days ago -
Race to combat mpox misinformation as vaccine rollout in DRC begins
A poll reveals that many Congolese are unaware of the deadly disease mpox due to spreading conspiracy theories and rumors. Efforts are being made to combat misinformation and ensure vaccine acceptance...
By The Guardian | 4 days ago
